Sarah K Whiteside

7PUBLICATIONS
75CO-AUTHORS
Molecular targetsInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 03, 2026
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species.

|Jul 19, 2024
Cross-talk between ILC2 and Gata3high Tregs locally constrains adaptive type 2 immunity.

Julie Stockis, Thomas Yip, Julia Moreno-Vicente

|Jul 12, 2024
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.

Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside

|Dec 15, 2023
Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion.

Sarah K Whiteside, Francis M Grant, Giorgia Alvisi

|Sep 30, 2022
BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis.

Charlotte J Imianowski, Sarah K Whiteside, Teresa Lozano

|Apr 10, 2021
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.

Sarah K Whiteside, Francis M Grant, David S Gyori

Pageof 2

Frequent Collaborators

6 joint publications

Rahul Roychoudhuri

4 joint publications

Klaus Okkenhaug

4 joint publications

Charlotte J Imianowski

4 joint publications

Jie Yang